Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission

J Infect. 2005 Nov;51(4):314-7. doi: 10.1016/j.jinf.2005.01.015.

Abstract

This study was to evaluate responsiveness to IFN-alpha and investigate the benefits of sustained response (SR) in patients who were presumed as being vertically transmitted in Korea. A total of 46 patients of presumed vertical transmission with biopsy-proven HBeAg-positive chronic HBV infection were treated with IFN-alpha and followed. We tried to find the factors associated with SR and compared the cumulative rate of HCC and survival between SR group and non-sustained/non-responder (NSR) group. HBeAg loss was acquired in 35% (16/46) within a year but SR was observed in 22% (10/46). Age <35 years and ALT levels >7xULN were significant favorable factors for SR (OR 0.56, 0.49, 95%CI 0.38-0.82, 0.29-0.81, respectively) (both P<0.05). There were no significant differences of cumulative HCC-free survival (100 vs. 68% at 12 years, P=0.36) and survival (100 vs. 73% at 12 years, P=0.3) between SR group and NSR group. In conclusion, age below 35 years old and serum ALT levels above 7xULN may predict IFN-alpha therapy-induced SR among them, although we cannot affirm the effects on HCC prevention or survival.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Alanine Transaminase / blood
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / prevention & control
  • Carcinoma, Hepatocellular / virology
  • Child
  • Evaluation Studies as Topic
  • Female
  • Hepatitis B e Antigens / analysis
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / transmission*
  • Humans
  • Infectious Disease Transmission, Vertical*
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Korea
  • Male
  • Middle Aged
  • Risk Factors

Substances

  • Antiviral Agents
  • Hepatitis B e Antigens
  • Interferon-alpha
  • Alanine Transaminase